金斯瑞(1548.HK)漲超10%創3年新高 傳奇生物將公佈最新研究成果
格隆匯5月31日丨金斯瑞生物科技(1548.HK)盤中拉昇一度漲10.6%報30.25港元,股價創2018年5月以來新高,市值591億港元;該股年內累漲超160%。公司日前公吿,非全資附屬公司傳奇生物將公佈關於靶向B細胞成熟抗原的嵌合抗原受體T細胞(CAR-T)療法西達基奧侖賽Ciltacabtagene Autoleucel的最新及更新結果,該療法用於治療復發和╱或難治性多發性骨髓瘤。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.